RPC
TEVA icon

Royal Palms Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Royal Palms Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.8M Sell
82,550
-6,240
-7% -$208K 2.46% 21
2026
Q1 		$2.67M Sell
88,790
-25,067
-22% -$806K 2.65% 20
2025
Q4 		$3.55M Buy
+113,857
New +$2.8M 4.22% 9

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Royal Palms Capital's TEVA Position: Q2 2026 in Review

Royal Palms Capital reduced its Teva Pharmaceuticals (TEVA) stake by 7% in Q2 2026, selling an estimated $208K and leaving 82,550 shares worth $2.8M. The position accounts for 2.46% of the portfolio, ranked #21.

Royal Palms Capital first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.55M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Royal Palms Capital held 82,550 shares of Teva Pharmaceuticals worth $2.8M as of Q2 2026.
  • Royal Palms Capital sold 6,240 Teva Pharmaceuticals shares in Q2 2026, an estimated $208K.
  • Teva Pharmaceuticals made up 2.46% of Royal Palms Capital's portfolio in Q2 2026, its #21 holding.
  • Royal Palms Capital first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Royal Palms Capital's Teva Pharmaceuticals position peaked at $3.55M in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Royal Palms Capital's 13F filing for Q2 2026, filed 7 Aug 2026.